（记者 胡玲） 2024年1至12月份，瑞普生物的营业收入构成为：兽用生物制品占比43.12%，兽用药物占比33.86%，宠 物供应链占比20.63%，其他占比2.38%。 每经AI快讯，瑞普生物（SZ 300119，收盘价：23.48元）8月25日晚间发布公告称，公司第五届第二十 六次董事会会议于2025年8月22日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于 <2025年半年度报告>及其摘要的议案》等文件。 每经头条（nbdtoutiao）——租下2.5万亩"试验田"，兽医学博士在非洲种粮：首季亩产250斤，打算扩至 10万亩，月薪1~2万元招人 ...

申联生物(688098)21日盘中股价大幅波动，截至发稿，该股跌约12%，成交近5亿元。此前的4个交易 日，该股已斩获3个涨停板。 公司日前在公告中指出，经自查，公司目前日常经营情况正常，未发生重大变化。市场环境或行业政策 未发生重大调整，产品研发、生产和销售等情况未出现大幅波动，内部生产经营秩序正常。 公司关注到近期市场对创新药业务关注度较高。公司于2025年2月6日披露《关于全资子公司对外投资暨 关联交易的公告》，公司通过全资子公司上海本天成生物医药有限公司向世之源增资6000万元并取得世 之源20.48%的股份，公司开始布局人用创新药领域。世之源拥有艾滋病治疗单克隆抗体药物(UB-421)、 抗过敏Anti-IgE单克隆抗体药物(UB-221)以及抗单纯疱疹病毒单克隆抗体药物(UB-621)等管线在中国内 地的临床及商业化权利。公司于2025年8月11日披露《申联生物医药(上海)股份有限公司投资者关系活 动记录表》，公司发布信息后，部分媒体也发布了相关报道。 截至公告披露日，世之源三个创新药管线尚处于不同的研发阶段。其中，UB-221已由世之源在中国内 地全面开启临床II期试验；UB-421与UB-62 ...

格隆汇8月19日｜申联生物(688098.SH)今日再度20CM涨停，为连续第三日涨停，报价15.4元，创2021年 3月以来新高。 申联生物昨晚发布股票交易异常波动公告称，经公司自查，并发函向控股股东、实际控制人核实，截至 本公告披露日，公司不存在应披露而未披露的重大事项。公司目前生产经营正常，生产经营未发生重大 变化。公司目前的主营业务是兽用生物制品，艾滋病单克隆抗体等创新药管线由联营公司扬州世之源生 物科技有限责任公司独立运营，相关业务具有研发周期长，投入大，研发风险高的特点。 ...

Group 1 - The core business of the company is veterinary biological products, while the innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [2] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [2]

Company Overview - Haili Biological's closing price on August 6 was 7.58 yuan, down 1.17%, with a rolling PE ratio of 26.75 times and a total market value of 4.97 billion yuan [1] - The company ranks 54th in the medical device industry, which has an average PE ratio of 53.93 times and a median of 37.81 times [1] Shareholder Information - As of March 31, 2025, Haili Biological had 31,505 shareholders, a decrease of 1,319 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Business Segments - The main business segments of Shanghai Haili Biological Technology Co., Ltd. are in vitro diagnostic reagents (IVD) and oral tissue repair and regeneration materials, with key products including veterinary biological products and medical devices [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved operating revenue of 61.79 million yuan, a year-on-year decrease of 12.11%, while net profit was 10.90 million yuan, a year-on-year increase of 393.11%, with a gross profit margin of 75.96% [1]

Group 1 - The stock price of Pulaike remained stable at 15.00 yuan as of August 5, 2025, with a trading volume of 28,287 hands and a transaction amount of 0.42 billion yuan [1] - Pulaike specializes in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine, covering four major series: swine, poultry, ruminants, and pets [1] - The company expects a net profit attributable to shareholders for the first half of 2025 to be between 107 million yuan and 122 million yuan, representing a year-on-year growth of 44.7% to 64.98%, driven by product structure optimization and market expansion [1] Group 2 - On August 5, 2025, the net outflow of main funds was 2.7613 million yuan, with a cumulative net outflow of 29.2306 million yuan over the past five trading days [1]

Group 1 - The core business of the company is the research, production, and sales of veterinary drugs, including veterinary biological products and chemical drugs [1] - The company completed the transfer of 48.4213% equity in Hunan Zhong'an Biological Pharmaceutical Co., Ltd. for a transaction amount of 115 million yuan, and still holds 20% equity after the transfer [1] - On July 30, the company's stock closed at 21.36 yuan, down 0.23% from the previous trading day, with a trading volume of 82,415 hands and a transaction amount of 176 million yuan [1] Group 2 - On July 30, the net outflow of main funds for the company was 10.5372 million yuan [2]

Core Viewpoint - Jinhe Biology announced the convening of its 28th meeting of the 6th Board of Directors on July 30, 2025, to review the full and summary reports of the 2025 semi-annual report [2] Revenue Composition - For the year 2024, the revenue composition of Jinhe Biology is as follows: - Veterinary chemical drugs account for 52.06% - Agricultural product processing accounts for 24.53% - Veterinary biological products account for 14.5% - Environmental protection business accounts for 6.04% - Others account for 2.54% [2]

Core Viewpoint - The financial performance of Pulaike Company shows significant growth in revenue and net profit for the first quarter, indicating strong operational efficiency and profitability despite a decline in annual figures for 2024. Financial Performance Summary - For Q1, Pulaike's operating revenue reached 278.62 million yuan, an increase of 18.32% year-on-year [1] - The net profit attributable to shareholders was 52.91 million yuan, reflecting a 93.75% increase compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 48.90 million yuan, up 84.27% year-on-year [1] - The basic earnings per share were 0.16 yuan, doubling from 0.08 yuan in the previous year [1] - The net cash flow from operating activities was 46.90 million yuan, a significant turnaround from a negative cash flow of 4.39 million yuan in the previous year, marking a 1,167.15% increase [1] Profitability Metrics - The gross profit margin for the reporting period was 59.71%, down 4.70% year-on-year but up 4.19% quarter-on-quarter [2] - The net profit margin was 18.99%, which increased by 7.39% year-on-year and 23.78% quarter-on-quarter [2] Expense Management - Total expenses for the reporting period were 102 million yuan, a decrease of 15.73 million yuan compared to the previous year [2] - The expense ratio was 36.50%, down 13.37% year-on-year [2] - Sales expenses decreased by 2.09%, while management expenses saw a significant reduction of 44.70% [2] - Research and development expenses increased by 2.24%, and financial expenses rose by 63.81% [2] Annual Performance Overview - For the full year 2024, Pulaike reported an operating revenue of 1.043 billion yuan, a decline of 16.77% year-on-year [5] - The net profit attributable to shareholders was 92.81 million yuan, down 46.82% compared to the previous year [5] - The basic earnings per share for the year were 0.27 yuan [5] Company Background - Pulaike Company, established on June 22, 2002, specializes in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [5]

Core Viewpoint - TianKang Pharmaceutical Co., Ltd. has completed its IPO counseling work with CITIC Securities, indicating a move towards public listing despite recent declines in revenue and profit [1][2]. Financial Performance - In 2024, TianKang Pharmaceutical reported a revenue of 1.052 billion yuan, a decrease of 0.29% year-on-year, and a net profit attributable to shareholders of 153 million yuan, down 8.44% [1]. - For the first quarter of 2025, the company generated a revenue of 220 million yuan, a decline of 28.32% compared to 307 million yuan in the same period of 2024, with a net profit of approximately 33.33 million yuan, down 52.16% from 69.66 million yuan [3]. Shareholding Structure - The two largest shareholders of TianKang Pharmaceutical are TianKang Biological Co., Ltd. holding 58.94% and Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. holding 10% [3]. - Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. holds 22.92% of TianKang Biological Co., Ltd., making it the controlling shareholder [3]. Management Changes - In 2024, several key management changes occurred: Chairman Yang Yan and Supervisor Zhao Qin resigned due to retirement age, while Pan Yiping was reassigned due to internal adjustments [4][5]. - Zhang Jie was appointed as the new Chairman, and other new appointments included Hao Yiding as Secretary of the Board and Kong Chuxin as Supervisor and Chairman of the Supervisory Board [5][6].